Abatacept for GVHD Prophylaxis in Pediatric Severe Aplastic Anemia Undergoing Unrelated Donor Hematopoietic Cell Transplant: A Single-Center Experience

Key Points

• Abatacept shows promise in reducing GVHD incidence in pediatric patients.
• In this cohort, reduction in GVHD was noted in children aged 5-17 years.
• Analysis included patients who received hematopoietic cell transplants from unrelated donors.
• Further studies are warranted to confirm these findings in larger, multi-center trials.